Superluminal Medicines Inc.
Min-Sun Park is a Senior Computational Chemist at Superluminal Medicines, Inc. since July 2023, focusing on computational methods for hit discovery and optimization targeting GPCRs. Prior to this role, Min-Sun served as a Staff Scientist at 1859 Inc., enhancing small molecule screening through computational structure-based virtual screening. Previous experience includes positions as a Structural Biologist III at Ambry Genetics, where Min-Sun interpreted genetic variations via protein structure analysis, and as a Scientist I at REG Life Sciences, engineering enzymes for industrial applications. Additional roles include postdoctoral research on membrane proteins at the Howard Hughes Medical Institute, and research associateships at the University of Washington, University of Rochester Medical Center, and Texas A&M University, with a foundation in enzymology and drug screening. Min-Sun holds a Ph.D. in Biophysics from the University of Rochester School of Medicine and Dentistry and a Master’s Degree in Bio-organic Chemistry from Texas A&M University.
This person is not in any teams
Superluminal Medicines Inc.
Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVIDIA and Gaingels.